Hepatologist, International Medical VP for NASH at Novo Nordisk, Associate Prof at BUSM (Volunteer status), NAFLD/NASH/liver/metabolic dz, tweets my own
Massachusetts, USA
Joined November 2011
- Tweets417
- Following205
- Followers652
- Likes897
Michelle T. Long retweeted
📢 CALLING ALL JUNIOR FACULTY: There is still time to apply for the 2024 AASLD-@EASLnews Masterclass. Check the eligibility requirements and finish your application by Monday, June 17! #LiverTwitter bit.ly/4edDL49
Michelle T. Long retweeted
Stephen, I’ve always admired your positive energy, thoughtful talks and your tenacity in chasing the most important questions in #MASLD. You’ve gone too soon, there was more to do and your legacy will be carried. I will miss your friendship and our exchange of kids pictures 💔
We’ve lost a friend and colleague who has had a monumental impact on MASH. Stephen brought charisma, endless energy, and joy along with deep knowledge and insights in MASH.
He had a magnetic force and we were all better for having been pulled into his orbit.
May our most beloved friend rest in peace @NoureddinMD @DrLoomba @NASH_and_coffee @MarcoArreseMD @VWSWong @AASLDtweets @AleksanderKrag @phil_newsome7
Thank you for sharing your story @KimberlyBlumen1 #thisiswhatgritlookslike #resilienceinacademicmedicine
I am going to write part of my (unfinished) story about the K to R transition as a woman in medicine and physician scientist in a multi-disciplinary research space in a tumultuous time. I am oversharing to encourage others in a similar 🚤#medtwitter #IDTwitter #AIMedEd. /1 of 20
Michelle T. Long retweeted
Congratulations Jen Lai for receiving the UCSF Academic Senate Distinction in Mentoring award. It’s a testament to Jen’s commitment, expertise, and positive impact as a mentor.
@UCSFLiverCenter @UCSFDOM @JessBRubin @JoeCullaro @egnij
Amazing honor to give the state-of-the-art lecture @NoureddinMD 🔥🔥
Michelle T. Long retweeted
NAFLD Article of the Week @IUGastro
Two must read on clonal hematopoiesis (CHIP) & CLD
➡️ IU group shows obesity & chr inflam cause and worsen CHIP @jclinicalinvest
➡️ Harvard group shows CHIP ⬆️ CLD, liver inflam & fibrosis @Nature
@kathleencoreyMD @NoureddinMD @QAnstee
Michelle T. Long retweeted
It's here!
30 consensus, evidence-based statements about Physical Activity and #NAFLD from @ACSM roundtable out today in @MSSEonline!
journals.lww.com/acsm-msse/A…
@fitaftercancer @DrMTLong @KathleenCoreyMD
@drbobsallis @AlinaAllenMD @conroylab @djrcuthbertson @CJAPugh
Michelle T. Long retweeted
Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis #NAFLD #FattyLiver #obesity #cirrhosis #livertwitter bit.ly/3Tia2Nj
Fantastic talk @JonathanStineMD on the science of exercise as medicine for #NASH and #NAFLD @GlobalEngage #2023NASHcongress take home point - exercise makes patients feel better and improves all aspects of #NASH
Michelle T. Long retweeted
Excited to be a part of this group of fantastic humans! Reach out to @RainbowinGastro if you want to join us!
New Comment - Overcoming disparities for sexual and gender minority patients and providers in #gastroenterology and #hepatology: introduction to Rainbows in Gastro
thelancet.com/journals/langa…
@RainbowinGastro #DEI #gitwitter #livertwitter
Michelle T. Long retweeted
Michelle T. Long retweeted
Congrats to all involved, especially my co Editors in chief @Alexfornergon @lucavalenti75 , the AEs I rely on more frequently @b_maasoumy @salvatore_petta @analleo @ProfJohnDillon @DrMTLong and everyone from the editorial team!
👋 Our new impact factor has increased to 8.754!
Thanks to the editorial board, our peer reviewers and the trust of the authors 🙏
Do you work in the field of Hepatology? Send us your manuscript 📨
#LiverTwitter
Excellent talk about future if AI in medicine with so many novel applications #ILC2022
Michelle T. Long retweeted
As promised, slides from this talk about outcomes in clinical trials in #NASH
tinyurl.com/2p9byh7w
Any comments, questions, let me know!
#LiverTwitter
@AlinaAllenMD @AlkhouriNaim
Really looking forward to presenting on outcomes in clinical trials in #NASH at the #CLM22 later today
Will bust some common myths about natural history and outcomes
Will also post my slides after the talk!
#LiverTwitter
Michelle T. Long retweeted
Thank you @AASLDtweets and @EASLnews for giving us the chance for having a consensus (“a general accord of different parts in affecting a given purpose”) on NAFLD nomenclature. All stakeholders deserve a voice. Efforts done for this cause are very much appreciated 👏🏻👏🏻👇📝
There has been much progress regarding the ongoing discussions over nomenclature for nonalcoholic fatty liver disease (NAFLD). The results will be discussed at a consensus conference planned for July 2022. More information will be available soon. bit.ly/3oSzUkJ
Michelle T. Long retweeted
Join this great liver conference. We had Harvey Alter who won the 2020 Nobel prize as a keynote speaker last time. Privileged to be part of it. @JasmohanBajaj @AlkhouriNaim @CLDFoundation @NASH_and_coffee @KowdleyMd #GITwitter #livertwitter #liver @AASLDtweets – at Los Angeles, CA
Michelle T. Long retweeted
Help us spread the word - new federal guidance out of @USDOL today that plans must cover follow up colonoscopy after a positive stool test.
